Key takeaways
- 200-250 UK PNH patients with EVH-dominant residual anaemia despite anti-C5 therapy (Leeds National PNH Registry)
- £20K-30K NICE standard Technology Appraisal QALY threshold, the bar both ravulizumab (TA698) and iptacopan (TA1000) have already cleared
- ~600 UK PNH patients on complement inhibition (Leeds National PNH Registry); ~1,500 total diagnosed
- 30-40% estimated PAS discount off UK WAC required to clear the NICE standard Technology Appraisal cost-effectiveness bar
PNH's binding constraint is NICE's standard £20,000-30,000/QALY bar, the same threshold both ravulizumab and iptacopan have already cleared. The EVH-dominant population is where a new asset has genuine room to differentiate.
Ravulizumab (Ultomiris, AstraZeneca) is NHS England's commissioned PNH standard of care via NICE TA698 (a standard Technology Appraisal, published 19 May 2021), dosed IV every eight weeks at a UK list price near £335,000/year with PAS, and administered at roughly 20 NHS PNH specialist centres. Switching friction in stable patients is high; a new entrant must show an EVH-specific or oral advantage to earn consideration. The one meaningful crack in ravulizumab's position is extravascular haemolysis (EVH): persistent anaemia despite adequate C5 blockade. Leeds National PNH Registry data, the UK's definitive 30-year PNH natural-history dataset, puts the EVH-dominant, transfusion-burdened cohort at roughly 200-250 of the ~600 UK patients on complement inhibition. That gap, not the broad PNH population, is where a pre-launch asset has room to move.
Despite PNH's ultra-rare prevalence, NICE has routed every approved complement inhibitor through the standard Technology Appraisal process rather than the softer Highly Specialised Technology (HST) pathway reserved for conditions affecting 500 or fewer patients a year in England. Ravulizumab cleared NICE as TA698 on the standard route, and iptacopan (Fabhalta, Novartis), the first oral Factor B inhibitor, has since cleared as TA1000, NICE's 1,000th published appraisal, with a final positive recommendation now in place. That precedent is the clearest available signal for a pre-launch asset: expect NICE's ordinary £20,000-30,000/QALY bar, not the ultra-rare threshold, regardless of how narrowly the indication is framed.
The pre-launch sequence follows from that precedent. Request a NICE pre-submission scoping meeting roughly 24 months ahead of anticipated MHRA approval and plan for a standard Technology Appraisal rather than assuming HST eligibility, since neither ravulizumab nor iptacopan received it despite PNH's ultra-rare status. Design the PAS in parallel: a modelled QALY gain of 0.4-0.6/year against a UK WAC near £250,000/year implies a required discount of roughly 30-40% to land inside the standard TA threshold. File for MHRA's Innovative Licensing and Access Pathway (ILAP) on the same 24-month clock to align MHRA and NICE evidence expectations early. And invest in Leeds National PNH Registry collaboration now: an EVH-burden analysis built on Leeds's longitudinal cohort is the strongest UK real-world evidence available to a pre-launch sponsor.
NICE-commissioned and pending PNH agents — UK, 2026
| Drug (Brand / INN) | Mechanism | Company | UK Status | Key Trial | NICE/NHS Route |
|---|---|---|---|---|---|
| Ultomiris (ravulizumab) | Anti-C5 mAb IV q8w | AstraZeneca | NHS TA698 commissioned 2021 | HERCULES | NICE TA698 (standard TA); NHS WAC ~£335K/yr with PAS |
| Fabhalta (iptacopan) | Oral Factor B inhibitor | Novartis | MHRA approved Aug 2024; NICE TA1000 recommended | APPLY-PNH | NICE TA1000 (standard TA); recommended |
Sources: NICE TA698 ravulizumab decision document; NICE TA1000 iptacopan decision document; Leeds National PNH Registry; NHS England Highly Specialised Services programme.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why has NICE routed every approved PNH agent through the standard Technology Appraisal rather than the Highly Specialised Technology pathway, and what does that mean for a new asset's QALY bar? • NICE precedent analysis (ravulizumab TA698, iptacopan TA1000) • why HST eligibility hasn't applied despite PNH's ultra-rare status • an EVH-dominant subpopulation framing versus a broad-indication framing, and what each implies for the required PAS discount
- How large and how identifiable is the EVH-dominant PNH population in the UK before MHRA approval? • Leeds National PNH Registry-based sizing of the transfusion-dependent, residual-anaemia cohort • NHS Blood and Transplant transfusion-frequency data • the diagnostic and identification pathway through NHS PNH specialist centres
- What PAS discount and MHRA/NICE regulatory sequence are needed to clear NICE's cost-effectiveness bar on the timeline MHRA approval demands? • PAS modelling against the standard TA threshold • MHRA ILAP application timing • the NICE pre-submission scoping meeting sequence • and how the iptacopan TA1000 recommendation sets the goalposts for a new entrant
What's inside
-
1 · The Binding Constraint 2 pp
- Why an EVH-specific or oral advantage, not broad efficacy, is the one credible entry point against ravulizumab's entrenched position
- How the 200-250 patient EVH-dominant cohort, not the full roughly 600-patient anti-C5 population, defines where a pre-launch asset can move
-
2 · Standard-of-Care Landscape & Entrenchment 5 pp
- Why ravulizumab's NICE TA698 commissioning, roughly £335,000/year list price and administration at about 20 NHS specialist centres creates high switching friction
- How iptacopan's TA1000 recommendation as an oral Factor B inhibitor sets the second competitive precedent a new entrant must clear
-
3 · Target Population & Unmet Need 5 pp
- How Leeds National PNH Registry data sizes the EVH-dominant, transfusion-burdened cohort at 200-250 patients
- Why persistent anaemia despite adequate C5 blockade, not the broad roughly 600-patient complement-inhibitor population, is the addressable unmet need
-
4 · Anticipated Payer & Access Posture 5 pp
- Why NICE has routed every approved PNH agent through the standard Technology Appraisal, not the Highly Specialised Technology pathway, despite ultra-rare status
- How a modelled 0.4-0.6 QALY/year gain against a roughly £250,000 WAC implies a 30-40% PAS discount to clear the standard £20,000-30,000/QALY bar
-
5 · The Assumption Register 2 pp
- What the Leeds registry-derived EVH cohort size, PAS discount and NICE pathway assumptions rest on, and where each could break
- Why treating ravulizumab and iptacopan's standard TA precedent as fixed, not as a bet on HST eligibility, is the load-bearing assumption
-
6 · KOL & Centre Readiness 3 pp
- Why NHS PNH specialist centre engagement and Leeds National PNH Registry collaboration must begin now, ahead of MHRA approval
- How the roughly 20 NHS PNH specialist centres administering ravulizumab define the readiness map a new entrant must build against
-
7 · Client Alignment Questions 2 pp
- What decisions on EVH-cohort framing, PAS discount tolerance and NICE scoping timing require client sign-off before pre-submission
- Why filing MHRA's Innovative Licensing and Access Pathway on the same 24-month clock as NICE scoping is a client alignment checkpoint, not a default
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers UK PNH launch readiness assessments built for pre-launch commercial, market access, and medical affairs teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your asset, target population, and the NICE pathway question you need answered.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment synthesises three research angles into a single UK PNH launch readiness view: competitive positioning against ravulizumab and iptacopan, target-population sizing anchored in the Leeds National PNH Registry, and anticipated NICE/NHS payer posture derived from the ravulizumab TA698 and iptacopan TA1000 precedent, both standard Technology Appraisals.
Sources: NICE TA698 ravulizumab decision document; NICE TA1000 iptacopan decision document; Leeds National PNH Registry and its published natural-history data; NHS England Highly Specialised Services (PNH) programme specification; NHS Blood and Transplant transfusion data.
- NICE pathway framing verified against the published TA698 ravulizumab decision and the TA1000 iptacopan decision, both standard Technology Appraisals
- Population and EVH-cohort figures verified against Leeds National PNH Registry published data
- PAS and WAC estimates verified against NICE TA698 cost-effectiveness modelling references
- No figure carried from model memory; every number traces to a named NICE, NHS, or registry source
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes a 24-30 page PDF covering the binding constraint, standard-of-care entrenchment, target population, and anticipated NICE/NHS payer posture; an editable Excel model (population sizing and PAS/QALY scenario grid); and a 12-15 slide PowerPoint readout. A 45-minute analyst call is included with every delivery.
Sources What sources does AXLRx use for a UK launch readiness assessment, and how are figures verified?
AXLRx builds from NICE technology appraisal documents (HST and standard TA decisions and scoping consultations), MHRA approvals, NHS England commissioned-service specifications, disease registries such as the Leeds National PNH Registry, and peer-reviewed trial publications. No figure is carried from model memory; every number is cited to a named source and cross-checked in an independent audit pass before delivery.
Customisation Can I tailor the assessment to my specific asset, population, or NICE pathway question?
Yes. The intake form captures your asset's mechanism, target subpopulation, and the specific NICE pathway or payer question you need answered — HST versus standard TA framing, PAS design, or KOL engagement sequencing, for example. A scoping call confirms scope before research starts.